微信公众号

官网二维码
中国癌症防治杂志

中国癌症防治杂志 ›› 2021, Vol. 13 ›› Issue (6): 647-652.doi: 10.3969/j.issn.1674-5671.2021.06.13

• 临床研究 • 上一篇    下一篇

miR-7及SP-1与非小细胞肺癌患者放疗敏感性的相关性研究

  

  1. 湖南师范大学附属第一医院（湖南省人民医院）呼吸与危重症医学科 
  • 出版日期:2021-12-25 发布日期:2022-01-07
  • 通讯作者: 李建民 E-mail：38918007@qq.com

Correlation of miR-7 and SP-1 with radiotherapy sensitivity in NSCLC patients

  • Online:2021-12-25 Published:2022-01-07

PDF (PC)

110

赞

摘要： 目的 探讨miR-7及其下游靶点特异性蛋白1（specific protein 1，SP-1）与非小细胞肺癌（non-small cell lung cancer，NSCLC）患者放疗敏感性的相关性。方法 收集湖南师范大学附属第一医院2018年7月—2020年9月收治的116例原发性NSCLC患者癌组织及其相应癌旁组织，并采集外周血。采用实时荧光定量PCR法测定组织和外周血血清中miR-7的表达水平，免疫组化检测SP-1蛋白表达水平，Logistic回归模型分析影响NSCLC患者放射敏感性的因素。结果 NSCLC患者癌组织中miR-7表达水平低于癌旁组织（P<0.001），SP-1阳性表达率高于癌旁组织（P<0.001）。Pearson相关分析显示，血清miR-7与癌组织中的miR-7表达呈正相关（r=0.492，P<0.001），SP-1表达阳性患者血清中的miR-7相对表达量低于阴性表达患者（P=0.005）。T3~4分期、TNM分期ⅢA~B期、有吸烟史、发生放射性肺损伤者血清和癌组织中的miR-7表达水平降低（均P<0.05）；癌组织中SP-1阳性表达率升高（均P<0.05）。与放射敏感组比较，放射抵抗组血清和癌组织中miR-7相对表达量降低（均P<0.001），SP-1阳性表达率升高（P<0.001）。受试者工作特征曲线显示，血清miR-7预测NSCLC患者发生放射抵抗的曲线下面积为0.822 （95%CI：0.746~0.897）。血清miR-7表达水平降低是放疗敏感性的危险因素（P=0.009）。结论 血清miR-7在预测放疗抵抗中具有良好的效能，miR-7及其下游靶分子SP-1可能是潜在的放疗增敏靶点。

关键词: 非小细胞肺癌, miR-7, SP-1, 放疗敏感性

Abstract: Objective To investigate the correlation of miR-7 and its downstream target specific protein 1(SP-1) with the radiosensitivity in non-small cell lung cancer (NSCLC) patients. Methods The tumor tissues, adjacent tissues and peripheral blood of 116 patients with primary NSCLC, admitted to the First Affiliated Hospital of Hunan Normal University from July 2018 to September 2020, were collected. The expression of miR-7 in tissue samples and peripheral blood serum were measured by real-time fluorescent quantitative PCR. The expression of SP-1 protein was detected by immunohistochemistry. The factors affecting the radiosensitivity of NSCLC patients were analyzed by the logistic regression model. Results The expression of miR-7 in tumor tissues of NSCLC patients was lower than that in adjacent tissues (P<0.001), while the positive expression rate of SP-1 protein was higher than that in adjacent tumor tissues (P<0.001). Pearson showed that serum miR-7 was positively correlated with the expression of miR-7 in tumor tissue (r=0.492, P<0.001), and serum miR-7 expression in NSCLC patients with positive SP-1 expression was lower than that in patients with negative SP-1 expression (P=0.005). The expression levels of miR-7 in serum and tissue of patients with T3-4 stage, TNM stageⅢA-B, smoking and radiation-induced lung injury were decreased (all P<0.05), and the positive rate of SP-1 was increased in cancer tissues (all P<0.05). Compared with the radiation sensitivity group, the relative expression of miR-7 in serum and tumor tissue of the radiation resistance group was decreased (all P<0.001), and the positive expression rate of SP-1 was increased (P<0.001). The receiver operating characteristic curve showed that the area under the curve of serum miR-7 to predict rodiotherapy resistance in NSCLC patients was 0.822 (95%CI: 0.746-0.897). Decreased serum miR-7 expression was a risk factor for radiotherapy sensitivity (P=0.009). Conclusions Serum miR-7 has a good efficacy in predicting radiotherapy resistance. miR-7 and its downstream targeted molecular SP-1 are potential radio sensitizing targets.

Key words: Non-small cell lung cancer, miR-7, SP-1, Radiotherapy sensitivity

中图分类号: 

  • R734.2